CClinicalTrials.gg
CompletedNCT06203886LumbaCure2303Updated Aug 29, 2024

Effect of the LumbaCure® Intervention on Elderly Patients Suffering From cLBP.

An interventional study of LumbaCure in Low Back Pain, sponsored by Odix. Completed at 1 site in Belgium. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Odix · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Study summary

The goal of this investigation is to evaluate the safety and efficacy of the LumbaCure® device in elderly people suffering from low back pain. The study is being carried out at several sites, in nursing homes, in order to reach the elderly patients most at risk of a sedentary lifestyle.

02

Conditions studied

  • Low Back Pain
03

In context

Back Pain

2,373 studies on the registry are indexed under Back Pain; 284 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 1,941 interventional studies indexed under Back Pain.

Browse Back Pain studies →

Lead sponsor

Odix is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Chronic or sub-acute low back pain (without "red flag")
  • The subject, a resident or worker at the investigation site (nursing home), over 60 years of age
  • Ability to communicate with the physiotherapist.
  • Ability to remain in a sitting position for at least 10 minutes.
  • A level of back pain > 2 on the numerical pain rating scale

Exclusion criteria

Exclusion Criteria:

  • Suspected or confirmed serious pathology (infection, fracture, cancer, inflammatory arthritis, ....) related to the back/spine.
  • Body weight > 120 kg
  • Subject is non-ambulatory or has severely reduced mobility.
  • Dominant component of radicular pain (common lumbago with distal radiation below the knee)
  • Radiculopathy
  • Severe cardiorespiratory disease
  • Dementia or significant cognitive impairment that prevents the participant from giving consent, completing study questionnaires or complying with recommendations.
  • Fracture or operation less than 3 months old of the spine, pelvis, hip or leg bones.
  • Known vertebral pathology other than osteoarthritis.
  • Major neurological disease, movement or motor neuron disorders
  • Fibromyalgia or other systemic rheumatic disease
  • Recent history of stroke or heart failure, unstable heart condition
  • Uncontrolled substance abuse disorders
  • Invasive procedures to relieve pain in the last 3 months
  • Acute or terminal illness
  • Any other medical condition considered by the study team to be a contraindication to the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Test Intervention arm

    LumbaCure robotic device

    Device: LumbaCure

Interventions

  • DeviceLumbaCure

    LumbaCure® is a device developed to induce specific mobilization of the lower back in patients requiring physical rehabilitation for orthopaedic disorders, particularly chronic low back pain.

06

What researchers measure

Primary outcomes

  1. Low back pain

    Mean intensity of low back pain during the last week, assessed on a numerical pain rating scale from 0 to 10

    Time frame: Change between baseline and Visit 3 (Day 28)

Secondary outcomes

  1. Functional mobility

    Change in the time taken to complete the time up and go (TUG) test. The TUG consists of measuring the time it takes a person to get up from a chair, walk 3 metres at their usual pace, turn around, return to the chair and sit down. Two attempts are made and the best time is recorded

    Time frame: Between baseline and visit 3 (day 28)

  2. Functional mobility

    Change in the time taken to complete the time up and go (TUG) test. The TUG consists of measuring the time it takes a person to get up from a chair, walk 3 metres at their usual pace, turn around, return to the chair and sit down. Two attempts are made and the best time is recorded

    Time frame: Between baseline and visit 2 (Day 14)

  3. Functional mobility

    Change in the time taken to complete the time up and go (TUG) test. The TUG consists of measuring the time it takes a person to get up from a chair, walk 3 metres at their usual pace, turn around, return to the chair and sit down. Two attempts are made and the best time is recorded

    Time frame: Follow-up period : between the end of the investigation period and 1 month post-study (Day 56 - Visit 4)

  4. Low back pain

    Weekly changes from baseline in mean intensity of low back pain during the last week, assessed on a numerical pain rating scale from 0 to 10.

    Time frame: Between baseline and each week through study completion, one month.

  5. Low back pain

    Current back pain intensity before and after each session, assessed on a numerical pain rating scale from 0 to 10.

    Time frame: Before and after each session [12 measures, 3x/week during one month]

  6. Low back pain

    Changes in mean intensity of low back pain in the last week, assessed on a numerical rating scale from 0 to 10, during the follow-up period between the end of the investigation period and 1 month post-study.

    Time frame: Follow-up : Between end of the investigation period [Day 28] and 1 month post-study.

  7. Overall satisfaction of the physiotherapist with the LumbaCure® intervention

    A single satisfaction score will be reported at the end of the intervention period by the physiotherapist: * How satisfied or dissatisfied are you with the ability of the LumbaCure® device intervention to improve your patient's low back pain condition (7 point scale)? * To what extent are you satisfied or dissatisfied with the ability of the LumbaCure® device to improve your patient's mobilisation (7-point scale)?

    Time frame: End of intervention period [Day 28]

  8. Overall patient satisfaction with the LumbaCure® intervention

    A single satisfaction score will be calculated at the end of the intervention period based on a series of three questions : * How satisfied or dissatisfied are you with the ability of the LumbaCure® procedure to improve your lower back pain (7 point scale)? * How satisfied or dissatisfied are you with the ability of the LumbaCure® procedure to improve your mobility? * How would you rate your overall experience with the LumbaCure® device (7-point scale)?

    Time frame: End of intervention period [Day 28]

  9. Risk of falling

    Change in the risk of falling between baseline and the end of the intervention period, visit 3 (day 28), assessed by the Tinetti test. This test is a comprehensive assessment of both balance and gait. It assesses the patient's ability to change position, maintain balance in different situations and walk.

    Time frame: Between baseline and the end of the investigation,visit 3 [Day 28]

  10. Risk of falling

    Changes in the risk of falling during the follow-up period assessed by the Tinetti test. This test is a comprehensive assessment of both balance and gait. It assesses the patient's ability to change position, maintain balance in different situations and walk.

    Time frame: Between the end of the investigation,visit 3 [Day 28] and one month follow-up

Other outcomes

  1. Safety of the device

    The number, intensity and severity of adverse events are reported before each LumbaCure session.

    Time frame: through study completion, one month

07

Study locations

1 site
  • ASBL " Mère Joséphine " - MRS Saint Joseph Blegny
    Blégny, Liège 4670, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06203886
Lead sponsor
Odix
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Dec 11, 2023
Primary completion
Jun 17, 2024
Completion
Jul 18, 2024
Last update
Aug 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion